Medite Cancer Diagnostics Inc (MDIT) 0.5500 $MDIT
Post# of 273242
Posted On: 09/16/2016 7:03:53 AM
Medite Cancer Diagnostics Inc (MDIT) 0.5500 $MDIT
MEDITE Cancer Diagnostics, Inc. Reports Second Quarter 32% Revenue Increase and Six Months 2016 Results
ACCESSWIRE - Mon Aug 29, 8:00AM CDT
ORLANDO, FL / ACCESSWIRE / August 29, 2016 / MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the "Company"
specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its second quarter and six months 2016 results.
MEDITE Receives China FDA Approval for "SureThin" Preservative Solution
ACCESSWIRE - Mon Jun 13, 1:45PM CDT
ORLANDO, FL / ACCESSWIRE / June 13, 2016 / MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the "Company" specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces that UNIC Medical, the Company's Chinese distribution partner received May 31, 2016 China FDA approval as a Class I in vitro diagnostic reagent for MEDITE's "SureThin" cell preservation solution.
MEDITE Cancer Diagnostics, Inc. Reports $9.9 Million in Revenue and Results for 2015
ACCESSWIRE - Wed Apr 13, 8:00AM CDT
ORLANDO, FL / ACCESSWIRE / April 13, 2016 / MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the "Company" specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its 2015 financial results.
MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11
PR Newswire - Thu Jan 07, 2:19PM CST
MEDITE Cancer Diagnostics, Inc. (OTC:MDIT, the "Company", specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco in San Francisco, Calif.
MEDITE Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results
PR Newswire - Tue Nov 17, 8:00AM CST
MEDITE Cancer Diagnostics, Inc., (OTCQB:MDIT, the "Company" specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces its third quarter and nine month 2015 results.
Investment by UNIC Technologies CEO Dr. Zhongxi Zheng for 5.06% of MEDITE Cancer Diagnostics, Inc. Highlights Digital Cancer Diagnostic Strategy
BusinessWire - Wed Sep 09, 8:18AM CDT
MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT) specializing in the development, manufacturing, and marketing of immuno-assays and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces an investment by UNIC Medical, Inc.'s Chairman and UNIC Technologies, Inc.'s CEO, Dr. Zhongxi Zheng, an MD in Pathology. His investment represents 5.06% of MEDITE's outstanding common shares after the investment. In exchange for Dr. Zheng's $1.738 million investment, MEDITE Cancer Diagnostics, Inc. issued 1,086,250 shares of unregistered common stock at the per share price of $1.60. These shares are exempt from registration under Regulation S of the Securities Act of 1933.
MEDITE Cancer Diagnostics, Inc. Announces Change of Auditor
PR Newswire - Thu May 14, 6:07PM CDT
MEDITE Cancer Diagnostics, Inc., ("Company," OTCQB symbol: "MDIT" specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces change of auditors.
MEDITE Cancer Diagnostics, Inc. Announces short Delay for 10k Filing of 2014 Financials
PR Newswire - Thu Apr 16, 6:00AM CDT
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases announces a delay in the filing of the Form - 10k with the Securities and Exchange Commission.
MEDITE Cancer Diagnostics, Inc. Announces Granted Patent "Lab-in-One Automation" System
PR Newswire - Fri Mar 20, 11:59AM CDT
MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and related diseases announced the recent decision of the German Patent Register to grant MEDITE the German priority patent for its Histology "Lab-in-one Automation" System. Based on this success MEDITE will finish its nationalization applications for USA, China and UK before April 4th, 2015.
MEDITE Cancer Diagnostics, Inc. Reports Second Quarter 32% Revenue Increase and Six Months 2016 Results
ACCESSWIRE - Mon Aug 29, 8:00AM CDT
ORLANDO, FL / ACCESSWIRE / August 29, 2016 / MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the "Company"
specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its second quarter and six months 2016 results. MEDITE Receives China FDA Approval for "SureThin" Preservative Solution
ACCESSWIRE - Mon Jun 13, 1:45PM CDT
ORLANDO, FL / ACCESSWIRE / June 13, 2016 / MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the "Company"
specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces that UNIC Medical, the Company's Chinese distribution partner received May 31, 2016 China FDA approval as a Class I in vitro diagnostic reagent for MEDITE's "SureThin" cell preservation solution. MEDITE Cancer Diagnostics, Inc. Reports $9.9 Million in Revenue and Results for 2015
ACCESSWIRE - Wed Apr 13, 8:00AM CDT
ORLANDO, FL / ACCESSWIRE / April 13, 2016 / MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the "Company"
specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its 2015 financial results. MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11
PR Newswire - Thu Jan 07, 2:19PM CST
MEDITE Cancer Diagnostics, Inc. (OTC:MDIT, the "Company"
, specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco in San Francisco, Calif. MEDITE Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results
PR Newswire - Tue Nov 17, 8:00AM CST
MEDITE Cancer Diagnostics, Inc., (OTCQB:MDIT, the "Company"
specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces its third quarter and nine month 2015 results. Investment by UNIC Technologies CEO Dr. Zhongxi Zheng for 5.06% of MEDITE Cancer Diagnostics, Inc. Highlights Digital Cancer Diagnostic Strategy
BusinessWire - Wed Sep 09, 8:18AM CDT
MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT) specializing in the development, manufacturing, and marketing of immuno-assays and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces an investment by UNIC Medical, Inc.'s Chairman and UNIC Technologies, Inc.'s CEO, Dr. Zhongxi Zheng, an MD in Pathology. His investment represents 5.06% of MEDITE's outstanding common shares after the investment. In exchange for Dr. Zheng's $1.738 million investment, MEDITE Cancer Diagnostics, Inc. issued 1,086,250 shares of unregistered common stock at the per share price of $1.60. These shares are exempt from registration under Regulation S of the Securities Act of 1933.
MEDITE Cancer Diagnostics, Inc. Announces Change of Auditor
PR Newswire - Thu May 14, 6:07PM CDT
MEDITE Cancer Diagnostics, Inc., ("Company," OTCQB symbol: "MDIT"
specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces change of auditors. MEDITE Cancer Diagnostics, Inc. Announces short Delay for 10k Filing of 2014 Financials
PR Newswire - Thu Apr 16, 6:00AM CDT
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases announces a delay in the filing of the Form - 10k with the Securities and Exchange Commission.
MEDITE Cancer Diagnostics, Inc. Announces Granted Patent "Lab-in-One Automation" System
PR Newswire - Fri Mar 20, 11:59AM CDT
MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and related diseases announced the recent decision of the German Patent Register to grant MEDITE the German priority patent for its Histology "Lab-in-one Automation" System. Based on this success MEDITE will finish its nationalization applications for USA, China and UK before April 4th, 2015.
(0)
(0)Scroll down for more posts ▼